---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-035941"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:57:20.375398+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC

## Summary
- 90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.
- 100% complete response in CIS patients (2/2); 88.8% high-grade recurrence-free survival in papillary disease.
- NDV-01 well tolerated; no treatment-related AEs >Grade 1, no discontinuations due to AEs.
- Study continues enrolling; 26 patients enrolled, 20 reached 3-month assessment, 7 at 6 months.
- Administration time <10 minutes; data support potential bladder-sparing outpatient therapy.

## SEC filing metadata
- accession: 0001213900-25-035941
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/0001213900-25-035941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/ea0239764-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-035941
- JSON: https://secwatch.observer/filing/0001213900-25-035941.json
- Plain text: https://secwatch.observer/filing/0001213900-25-035941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.